Skip to content

AMIStem-H Radiographic Analysis

THP AMIStem-H: Open, Retrospective and Prospective, Monocentric, Non Randomised Observational Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02829866
Enrollment
289
Registered
2016-07-12
Start date
2010-09-30
Completion date
2021-10-31
Last updated
2023-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arthroplasty, Hip, Replacement

Brief summary

Total hip replacement (THP) is widely used for hip osteoarthritis treatment. Surgeons are constantly looking to improve all aspects related to this procedure weather is improvement of implant design, instrumentation or surgical technique. Excellent clinical and radiological results were observed at medium and long term in the last years for AMIStem system. This observational study has the objective to survey hip prosthesis stability and function of the operated hip in patients who are not exposed to surgical risks. The principal investigator will contact all patients in order to perform the follow-up visit according to standard practice. Patients operated between January 2010 and December 2011 will be invited in the study during the clinical visit organised according to standard practice. Preoperative clinical and radiological data, intraoperative details and postoperative follow-up data at 1-year will be retrospectively collected. Five-year and ten-year data will be prospectively collected after inclusion in the study.

Interventions

DEVICEAMIStem-H

Sponsors

Medacta International SA
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient who has received a total hip arthroplasty between January 2010 and December 2011 2. Patient who has received an AMIStem H femoral component 3. Patient who have signed the information letter in order to give agreement for the clinical data treatment

Exclusion criteria

1. Minor patient 2. Pregnant or breast feeding woman 3. Any patient who cannot or will not provide informed consent for participation in the study

Design outcomes

Primary

MeasureTime frame
Radiological analysis of radiolucency lines presence according to Gruen zone classification5 year

Secondary

MeasureTime frame
radiological assessment of femoral deformation5 year, 10 year
radiological assessment of femoral stem subsidence5 year, 10 year
radiological assessment of cortical bone density5 year, 10 year
radiological assessment of calcar resorption5 year, 10 year
Radiological analysis of radiolucency lines presence according to Gruen zone classification10 year

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026